Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib plus pembrolizumab (L plus P) in the phase 3 CLEAR trial
Keizman, D. Bedke, J. Staehler, M. D. Matveev, V. B. George, S. Hutson, T. E. Vaishampayan, U. N. Merchan, J. R. Eto, M. Rha, S. Y.
Keizman, D.
Bedke, J.
Staehler, M. D.
Matveev, V. B.
George, S.
Hutson, T. E.
Vaishampayan, U. N.
Merchan, J. R.
Eto, M.
Rha, S. Y.
Abstract
Description
Date
2025
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Keizman D, Bedke J, Staehler MD, Matveev VB, George S, Hutson TE, et al. Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib plus pembrolizumab (L plus P) in the phase 3 CLEAR trial. JOURNAL OF CLINICAL ONCOLOGY. 2025 FEB 10;43(5_SUPPL):531-. PubMed PMID: WOS:001454684700041. English.